Search
for
Sort by
Research 31–60 of 1000+
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Cetuximab Induced Hidrocystomas: A Case Report
- The ginseng pimple: an inflammatory papule following ginseng consumption
- Rosacea and Rosacea-like Demodicldosis
- Nilontinib induced keratosis pilaris atrophicans
- Psychoactive drugs and skin
- Methotrexate/tacrolimus/voriconazole
- Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature
- Cutaneous Adverse Events in Patients with Chronic Hepatitis C during Treatment with Directly Acting Antiviral Agents: A cohort study
- The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
- Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
- Drug-induced skin reactions: a pathologist viewpoint
- Fixed-Drug Eruption due to Dextromethorphan
- Cutaneous Drug Reaction Case Reports
- Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10‐year dataset in Singapore
- Benign Cutaneous Eruptions After Transplantation
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Chemotherapy and Cutaneous Drug Reactions
- Drug-Induced Skin, Nail and Hair Disorders
- Anticonvulsant-Induced Cutaneous Reactions
- Maculopapular Drug Eruption Caused by Finasteride: A Case Report
- Cutaneous signs in COVID ‐19 patients: A review
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- A clinical study of cutaneous adverse drug reactions
- Cutaneous Adverse Drug Reactions (CADRs) to COVID19 vaccines: A case series
- Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms
- Cutaneous adverse drug reaction associated with topical use of benzyl benzoate in a dog
- Drug-induced acne
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Cutaneous lupus erythematosus. Diagnostic and therapeutic recommendations of the Polish Dermatological Society